This is a pre-copyedited, author-produced version of an article accepted for publication in [ 
INTRODUCTION
The epidemiology, clinical presentation, mortality and neurological sequelae of cryptococcosis due to Cryptococcus gattii (CG) differ from those of its sibling species, Cryptococcus neoformans (CN) [1] [2] [3] . Management principles are based on randomized clinical trials of CN disease in HIV-infected patients [4] , case reports of CG infection [5] [6] [7] and expert opinion.
In a contemporary Australian series of 86 patients with CG infection, mortality was increased in immunocompromised patients whilst initial cerebrospinal fluid (CSF) cryptococcal antigen (CRAG) titres of ≥256 predicted death and/or neurological sequelae in central nervous system (CNS) disease [3] . Raised intracranial pressure (ICP), a predictor of mortality in CN meningo-encephalitis [4] , was frequent at presentation (66% where measured) and 9% of patients developed immune reconstitution syndrome (IRIS) [3] . We now describe the management of cryptococcal infection and its complications in these patients, and compare this with the Infectious Diseases of America (IDSA) Clinical Practice Guidelines for CG cryptococcosis [4] .
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METHODS
Study Design
The Australia and New Zealand Mycoses Interest Group conducted a nationwide study of CG infection in adults (January 2000-December 2007) with approval from human ethics review committees [3] . Clinical, laboratory and radiological data, disease complications (raised ICP, hydrocephalus, IRIS, neurological sequelae) and patient outcomes were recorded. Treatment details included: antifungal therapy (type, daily dose, duration); use of corticosteroids or immune-modulators and surgery (excision, CSF shunt placement). Data were collected at diagnosis to 14 days after starting antifungal therapy and at 6 weeks, 6 months and 12 months [3] ; total duration of antifungal therapy was also recorded.
Definitions
Only culture-confirmed CG infections were included. Cryptococcal meningo-encephalitis was defined by CG isolation from CSF. Brain involvement was diagnosed by a radiologist's report of mass lesions (≥ 1cm diameter) or other parenchymal abnormalities e.g. vasculitic lesions, without an alternative diagnosis. Abnormal neurology was defined as previously described [8] . An opening CSF pressure ≥25 cm water was considered elevated [4] . Induction therapy was the initial (intensive) antifungal regimen given for ≥3 consecutive days [9] . Consolidation/maintenance therapy, subsequently referred to as eradication therapy (see discussion), was defined previously [4, 9] . Re-induction comprised intensified therapy following poor response to induction or eradication therapy, or worsening of symptoms [9] .
IRIS was diagnosed when symptoms or radiological features consistent with inflammation worsened or appeared following a clinical and/or microbiological response to anticryptococcal therapy, and cultures were negative [3, 10, 11] . Clinical outcomes included allcause mortality; progressive disease or failure (worsening clinical symptoms/signs); stable disease (no improvement in symptoms/signs); partial response (≤50% resolution of A c c e p t e d M a n u s c r i p t 7 Clinical responses at 12 months were complete in 33% of 85 patients, partial in 48%, and stable in 3.5%. Mortality was 13.6% in patients with CNS disease and 11% in those with isolated lung infection. There were no relapses; all patients with a partial response or stable disease at 12 months were subsequently cured.
RESULTS
Seventy
Antifungal therapy
All patients were treated; induction regimens are summarized in Table 1 . Overall, 73 of 86 patients (85%) received amphotericin B (AMB), 74% in combination with 5-flucytosine (5FC) and 15% received fluconazole monotherapy (Table 1) .
One patient with isolated fungemia received cAMB for 3 days and the other, fluconazole for 8.5 months. The patient with osteomyelitis received cAMB plus 5-FC for 14 days followed by fluconazole for 6.5 months. All 3 had complete responses at 12 months.
Isolated pulmonary disease
Clinical data, treatment and outcomes of 10 patients with isolated lung disease are shown in Table 2 . Seven had moderate-to-severe lobar/generalized consolidation with or without mass lesions; 2 had single large (5-6 cm diameter) cryptococcomas. Seven patients received induction therapy with an AMB formulation (median 2 weeks; mean 3.9; range 1-8), 6 in combination with 5-FC. Conventional AMB (cAMB; 0.7-1.0 mg/kg daily) was initiated in all 7 cases but 2 were switched to liposomal AMB (LAMB; 4 mg/kg daily) due to renal impairment after 2 and 16 days, respectively. Neither of 2 kidney transplant recipients (Table A c c e p t e d M a n u s c r i p t 8 2) treated with fluconazole monotherapy achieved a complete response at 12 months.
Azole eradication therapy was used in nine patients, typically fluconazole 400-800 mg daily ( Table 2 ). Total duration of therapy was 24-208 weeks (mean 65.8; median 41). No lesions were resected surgically.
CNS disease
Of 73 patients, 25 (34%) achieved a complete clinical response, 33 (45%) a partial response, and 10 (13.6%) who failed therapy, died. AMB was initiated in 64 patients (88%), 57 (78%) in combination with 5-FC, for a median of 6 weeks (LQ-UQ 3-8; Table 3 ). All patients received cAMB initially but 31 (48.4%) were switched to L-AMB after a median of 8 days due to renal impairment.
Nine patients (12%) received fluconazole induction therapy, 400-1600 mg daily; modal dose 400 mg (Tables 3, 4); 7 (78%) required re-induction with AMB plus 5-FC due to clinical failure after a median of 28 days though 1 patient was later diagnosed with IRIS; the daily fluconazole dose in these 7 patients was 400 mg (n=5), 1600 mg (n=1) and 800 mg (n=1). Five patients treated initially with AMB plus 5FC received re-induction therapy (Table   3) for presumed treatment failure, later confirmed as IRIS in 4 cases. Fluconazole-and AMBtreated patients were equally likely to manifest one or more of CSF, brain or lung infection (Table 4) who received a total of 9-12 months of therapy: 6 had a complete, and 9, a partial response (response unknown in 3). All 10 deaths occurred in patients treated with AMB with/without A c c e p t e d M a n u s c r i p t 9 5-FC; 7 of them were immunocompromised. Proportionately more patients with CNS infection than with isolated lung disease were treated initially with AMB plus 5-FC (78% vs. 60%) but these differences were not significant (P = .2).
Raised Intracranial Pressure
CSF pressures, measured in 48 patients, were elevated in 31 (66%), 23 at diagnosis and a further 8, at 14 days; 8 patients (26%) had ICPs >35 cm water. Median time from onset of symptoms to CG diagnosis was 26 days (LQ-UQ 21-42) in patients with raised ICP and 29 days, [LQ-UQ 14-120], in those with normal ICP (P > 0.05); in all cases it was <48 hours from presentation to medical care.. Mortality was 19%. Raised ICP was associated with abnormal neurology at presentation and neurological sequelae (4 patients had visual loss) and/or death at 12 months but not with concomitant/late hydrocephalus or serum CRAG titers of ≥256 (Table 5) .
Elevated ICP was managed with daily/second daily lumbar punctures (LPs) in 13 patients, 6 of whom later received a CSF drain or shunt. Drains/shunts were inserted as primary ICP management in 11 (data unavailable for 7). Overall lumbar or extraventricular (EVD) drains were placed in 9 patients (median 27 days; range 4-36) for raised ICP and lumbar-peritoneal or ventriculo-peritoneal shunts in 13 (median 42 days; range 13-124 days) including 5 who had both procedures. Shunts were inserted in an additional 5 cases to treat concomitant hydrocephalus. The regimens and durations of induction and total antifungal therapy were similar in patients with/without raised ICP (Table 5 ). Eight patients received corticosteroids to treat raised ICP per se and 2, to reduce cryptoccocoma-associated edema.
Hydrocephalus
Obstructive hydrocephalus was identified by cerebral imaging in 22 (30%) patients with CNS cryptococcosis, 18 within 2 months and 4, 2-12 months after presentation. Brain cryptococcomas were present in 9 cases (5 had large single lesions and 3, multiple lesions).
Ten patients with early hydrocephalus also had raised ICP. Fourteen (64%) patients had CSF drains (n=7) or shunts (n=10) placed a median of 14 days (range 3-504) after diagnosis with antifungal drugs being introduced at time of placement. Shunts remained in situ long-term and in most cases, indefinitely. Twenty patients received induction therapy with AMB with (n=17) or without (n=3) 5-FC. The remaining 2 failed fluconazole therapy and were reinduced with AMB and 5-FC. Thirteen patients were treated with corticosteroids, 5 for cryptococcoma-associated edema, 4 for concomitant raised ICP and in 4 the indication was uncertain. Three patients (13.6%) died.
Other surgery
Lung lobectomy was performed at presentation for suspected malignancy in 3 of 9 patients with CNS plus lung infection, and in 2, at 8 and 30 months, to remove large lung lesions unresponsive to therapy. Resection of brain lesions (all cerebellar) was performed at diagnosis in 2 patients for suspected malignancy and at 12 months for therapeutic failure in a further 2; one of these was diagnosed with IRIS-like syndrome.
IRIS
Eight patients developed an IRIS after 6 weeks-12 months, while receiving azole eradication therapy. Two were immunocompromised and 1 was pregnant (Table 6 ). New and/or enlarging brain lesions with surrounding edema were universally present and 4 patients developed new neurological deficits, including blindness. One individual developed a concomitantly enlarging lung mass and new sub-carinal lymphadenopathy. Risk factors for IRIS included female sex, brain involvement at presentation, concurrent brain, CSF and lung disease, and higher median CD4 counts. CSF mononuclear leukocyte counts, and protein and glucose concentrations at diagnosis of cryptococcosis were similar in patients with and without IRIS (Table 6 ).
Five patients were re-induced with AMB with/without 5-FC; 3 also received interferon-gamma for presumed therapeutic failure and in 5, corticosteroids were either commenced or doses were increased to reduce cerebral edema. Cerebral imaging abnormalities returned to pre-IRIS appearances within 4-6 months. No patient died but 4 had persistent neurological sequelae at 12 months including the 3 who received interferongamma.
DISCUSSION
This large study of therapy and long-term outcomes of CG cryptococcosis is unique and shows that despite antifungal and supportive therapy, CG-associated morbidity is substantial.
To eradicate infection, longer antifungal treatment courses than those used in CN cryptococcosis [4] are required. Our data suggest that in both isolated lung and CNS cryptococcosis, induction therapy with AMB plus 5-FC leads to better outcomes than with fluconazole.
Lung disease: Based primarily on case reports, IDSA guidelines recommend 4-6 weeks of induction therapy with AMB plus 5-FC for large/multiple CG cryptococcomas [4, 7, [12] [13] [14] although fluconazole has been effective in mild-to-moderate CG lung disease [13] and HIV-negative patients with CN lung infection [9, 15] . In our series, initial selection of AMB +/-5-FC was likely driven by typical, radiologically-extensive, disease (80% patients) though not by specific radiological abnormalities or host immunocompromise. Our data suggest that 2 weeks induction therapy is sufficient in isolated lung disease. Fluconazole eradication therapy was continued, with a total treatment duration of 12 months, similar to that recommended for CN infection [4] . No patients relapsed although 4 required > 12 months' therapy to achieve cure. Fluconazole induction therapy was given to 2 kidney transplant recipients to avoid AMB-nephrotoxicity and consequent poor outcomes in such patients [16] .
CNS disease
The IDSA guidelines, informed by small series [2, 6, 7, 17] , recommend induction, consolidation and suppressive treatment for CNS disease due to CG [4] . A key finding of this study is that initial AMB plus 5-FC is essential in patients with CG: 80% of patients receiving AMB had a complete/partial clinical response at 12 months. Conversely, 78% of those receiving primary fluconazole failed therapy (although 1 had IRIS); Noting that the number of patients was small (n=7), therapeutic failure was not correlated with A c c e p t e d M a n u s c r i p t 13 fluconazole dose. Optimal duration of induction therapy for CG meningitis is uncertain; in our study, 6 weeks was used most commonly, consistent with recommendations for CN infection in immunocompetent hosts (4-6 weeks) [4, 18] . We have substituted the term "eradication therapy" for "consolidation/maintenance therapy" because fluconazole (typically 400 mg/day) was continued throughout the post-induction treatment period, "maintenance" therapy is not needed in the absence of ongoing immunosuppression and there were no late relapses (5-7 years) in this or a previous study [17] . A total of 6-12 months of therapy is recommended in CN patients [4] yet >70% of our patients received much longer courses (IQR 14-22 months). Healthy hosts with CG infection have historically received longer courses of antifungals than immunosuppressed patients with CN disease [2] . The optimal duration of therapy is also uncertain. Details of antifungal therapy [6, 19, 20] are absent from previous reports, or therapy was not stratified by site of infection [7] . Although the 10 deaths occurred in AMB-treated patients, all were severely ill and 7, immunocompromised; host immunocompromise is a risk factor for mortality [3] . We recommend a single treatment regimen in CNS infection due to CG, independent of host immune status.
Voriconazole or posaconazole were rarely used as induction or eradication therapy. In 2 patients, fluconazole caused alopecia, and voriconazole was substituted with good outcomes. Fluconazole eradication therapy remains appropriate in Australia; notably CG isolates with minimum inhibitory concentrations (MICs) of >8 μg/ml are rare (modal, range and geometric mean MICs of 4, 0.75-8 and 2.98 μg/ml, respectively; supplementary Table S1 and unpublished data). Surveillance of azole susceptibility is ongoing, given reports of some CG isolates with fluconazole MICs >8 µg/ml [14, 21, 22] and a reported association with genotypes not common in Australia, (eg. VGII and its subtypes) [21, 22] though the clinical significance of these elevated MICs is unknown. A c c e p t e d M a n u s c r i p t 14 Although c-AMB was the AMB formulation prescribed initially, 46.5% of patients were switched to LAMB (4 mg/kg daily) due to AMB-induced nephrotoxicity. Lipid AMB formulations and cAMB appear to be of equivalent efficacy in cryptococcal meningitis associated with HIV/AIDS and organ transplantation, [4] . Our data suggest that this is also true of CG cryptococcosis, although there are no comparative efficacy studies of c-AMB with lipid formulations in non-HIV, non-transplant populations.
Raised ICP was more common in patients presenting with abnormal neurological features but unlike in HIV/AIDS patients, not those with CSF CRAG titres (≥256) [23] . CSF pressure control is a critical determinant of outcome [4] ; in our study, raised ICP was associated with neurological sequelae and/or death at 12 months with 25% of such patients sustaining visual loss. Management of raised ICP in CG infection has not been investigated previously [6, 24, 25] . Raised ICP was controlled by daily/second daily LPs in only 45% with the remainder requiring insertion of CSF drains/shunts, at a median of 4-6 weeks (range 0.6-17). We cannot readily explain the apparent lag of 4-6 weeks prior to surgical correction of raised ICP, but recommend early neurosurgical review in all cases of raised ICP if frequent LPs fail to control CSF pressure after 1-2 weeks. Corticosteroids were used in 8 patients.
However, this approach is reportedly of no benefit in HIV/AIDS patients and may increase mortality [4] .
Hydrocephalus was frequent (30%) and can occur late. Shunt insertion was usually required and should be considered early. Shunts may be placed during active infection as long as effective antifungal therapy has been introduced [4, this study]. Resection of extensive pulmonary or cerebellar cryptococcomas was undertaken after 8-30 months in 4 patients with progressive disease; post resection, one was diagnosed with a cerebellar IRISlike syndrome. The impact of early resection on duration of antifungal therapy is unknown.
has occasionally been described in CG infection including in association with pregnancy [26- 28]; 1 of our patients presented post-partum. Risk factors included female sex, initial presentation with brain, or brain, meningeal and lung, involvement, and a higher median CD4 count; enlarging/new brain lesions were the predominant presenting feature. Interestingly, initial CSF leukocyte counts, protein and glucose, and high cryptococcal loads (positive India Ink stain and CSF CRAG titres of ≥256) were similar in patients with and without IRIS, contrasting with IRIS in HIV-associated cryptocococal meningitis, where low initial CSF leukocyte counts and protein levels were risk factors [27] . In HIV/AIDS and organ transplant patients, IRIS correlates with recovery of immune function and reduction of immune suppression, respectively [4, 29] . It is proposed that in healthy hosts, cryptococcal capsular polysaccharide induces a Th2 anti-inflammatory cytokine response, which is then replaced by pro-inflammatory Th1 responses following response to antifungal therapy; in some cases the latter are sufficiently robust to cause IRIS [30] .
Based on reported cases and the present study, IRIS develops 4 weeks to as long as 12 months after initiating antifungal drugs. Its recognition is important as it can be misdiagnosed as clinical failure; indeed 5 of our 8 patients received unnecessary re-induction AMB and 5FC. Further, 3 also received interferon-gamma, the use of which carries a theoretical risk of exacerbating IRIS due its pro-inflammatory effect. Prognosis is good. Corticosteroids were used successfully to control symptoms and cryptocccoma-associated edema.
In summary, key points highlighted by this CG study are: induction therapy with AMB plus 5-FC is indicated in patients with CNS disease; 6 weeks is standard. In lung disease, 2 weeks of induction AMB plus 5-FC is likely sufficient. Eradication therapy with fluconazole is appropriate to complete total therapy of 18 months in CNS disease and 12 months in lung infection, longer than that recommended for CN infection. Routine 
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